Daiichi to market Sonus agent in Asia

Article

Ultrasound contrast developerSonus Pharmaceuticals has licensed distribution rights for itsEchoGen intravascular agent to Daiichi Pharmaceutical of Japan.Under the agreement, Daiichi will market and distribute EchoGenin Japan and several other Asian

Ultrasound contrast developerSonus Pharmaceuticals has licensed distribution rights for itsEchoGen intravascular agent to Daiichi Pharmaceutical of Japan.Under the agreement, Daiichi will market and distribute EchoGenin Japan and several other Asian nations, Bothell, WA-based Sonusannounced last month.

Daiichi will guide clinical development of EchoGen and willmanage its registration with the Japanese Ministry of Health andWelfare. Sonus will receive milestone payments from Daiichi.

EchoGen is entering phase-two clinical trials in the U.S.

Related Videos
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2023 MJH Life Sciences

All rights reserved.